← Leaderboards
Junran Zhang
Ohio State University
$6,141,970
Attributed
$6,141,970
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $989.6K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,141,970 · 6
By mechanism
R01$4,972,618 · 3
R21$1,169,352 · 3
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- David P Carbone$20,647,321
- Kinh Luan Phan$12,331,438
- Anna E Vilgelm$2,524,271
- Xuefeng Liu$6,815,737
- Jennifer A. Woyach$6,733,332
Others in their field
Top investigators on “Novel Strategies”
- Judith S. Currier · University Of California Los Angeles$321,300,358
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$305,871,236
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$303,952,589
- Richard A Gibbs · Baylor College Of Medicine$295,698,028
- Constance Ann Benson · University Of California, San Diego$278,253,569
- Dennis R. Burton · Scripps Research Institute$256,423,824
Research focus
Novel StrategiesCellsClinical TrialsMalignant NeoplasmsCancer PatientCancer CellResponseCell SurvivalOncogenicSignal TransductionGenome-WideCancer TherapyCell LineTreatment StrategyReplication StressTumorChek1 GeneLoss Of FunctionBaseDna DamagePhosphotransferasesProtein ExpressionAtaxia Telangiectasia Mutated ProteinBiological Adaptation To Stress
Grant awards (22)
Targeting cholesterol metabolism and replication stress response in cancer therapy$356,850
R01 · FY2025 · CA · contact PI
Targeting cholesterol metabolism and replication stress response in cancer therapy$339,008
R01 · FY2024 · CA · contact PI
B55 alpha deficiency as a therapeutic target in cancer$325,395
R01 · FY2024 · CA · contact PI
Targeting cholesterol metabolism and replication stress response in cancer therapy$349,713
R01 · FY2023 · CA · contact PI
B55 alpha deficiency as a therapeutic target in cancer$229,685
R01 · FY2023 · CA · contact PI
Targeting cholesterol metabolism and replication stress response in cancer therapy$349,713
R01 · FY2022 · CA · contact PI
B55 alpha deficiency as a therapeutic target in cancer$349,713
R01 · FY2022 · CA · contact PI
Targeting cholesterol metabolism and replication stress response in cancer therapy$356,850
R01 · FY2021 · CA · contact PI
B55 alpha deficiency as a therapeutic target in cancer$356,850
R01 · FY2021 · CA · contact PI
Interruption of squalene epoxidase and DNA damage response in cancer therapy$182,325
R21 · FY2021 · CA · contact PI
Interruption of cholesterol metabolism and replication stress response in cancer therapy$401,115
R21 · FY2020 · CA · contact PI
B55 alpha deficiency as a therapeutic target in cancer$369,660
R01 · FY2020 · CA · contact PI
Interruption of squalene epoxidase and DNA damage response in cancer therapy$218,790
R21 · FY2020 · CA · contact PI
Exploring potential biomarkers predictive of response to ATR and CHK1 inhibitors$197,472
R21 · FY2019 · CA · contact PI
Exploring potential biomarkers predictive of response to ATR and CHK1 inhibitors$169,650
R21 · FY2018 · CA · contact PI
THE ROLE OF NEDD4-1 IN IGF-1R SIGNALING$301,258
R01 · FY2016 · CA · contact PI
THE ROLE OF NEDD4-1 IN IGF-1R SIGNALING$325,775
R01 · FY2015 · CA · contact PI
THE ROLE OF NEDD4-1 IN IGF-1R SIGNALING$316,002
R01 · FY2014 · CA · contact PI
THE ROLE OF NEDD4-1 IN IGF-1R SIGNALING$4,971
R01 · FY2013 · CA · contact PI
THE ROLE OF NEDD4-1 IN IGF-1R SIGNALING$325,775
R01 · FY2012 · CA · contact PI
THE ROLE OF NEDD4-1 IN IGF-1R SIGNALING$252,258
R01 · FY2011 · CA · contact PI
THE ROLE OF NEDD4-1 IN IGF-1R SIGNALING$63,142
R01 · FY2011 · CA · contact PI